Gilead Sciences, Inc. (GILD) financials: revenue, earnings and cash flow
Fiscal 2016–2025 + TTM · from SEC filings · data as of November 13, 2026
Summary
Gilead Sciences’s revenue went from $30.4B in fiscal 2016 to $29.4B in fiscal 2025, a decline of about 0.4% a year.
Net income in fiscal 2025 was $8.5B, a net margin of 28.9%; the best year in this period was 2016 with $13.5B.
Over the twelve months to September 30, 2026, revenue was $31.0B and net income -$3.9B.
Free cash flow was $9.5B in fiscal 2025 and positive in 10 of the 10 years shown.
The diluted share count fell 8% over the period (buybacks).
Revenue, profit and cash flow by year
Income statement
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $31.0B | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B | $24.7B | $22.4B | $22.1B | $26.1B | $30.4B |
| Gross profit | $24.8B | $23.2B | $22.5B | $20.6B | $21.6B | $20.7B | $20.1B | $17.8B | $17.3B | $21.7B | $26.1B |
| Operating income | -$2.4B | $10.0B | $1.7B | $7.6B | $7.3B | $9.9B | $4.1B | $4.3B | $8.2B | $14.1B | $17.6B |
| Net income | -$3.9B | $8.5B | $480M | $5.7B | $4.6B | $6.2B | $123M | $5.4B | $5.5B | $4.6B | $13.5B |
| EPS (diluted) | $-3.16 | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 |
| R&D | $6.3B | $5.8B | $5.9B | $5.7B | $5.0B | $4.6B | $4.9B | $9.1B | $5.0B | $3.7B | $5.1B |
| Revenue growth | — | +2.4% | +6.0% | −0.6% | −0.1% | +10.6% | +10.0% | +1.5% | −15.2% | −14.1% | −6.9% |
Cash flow
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $14.5B | $10.0B | $10.8B | $8.0B | $9.1B | $11.4B | $8.2B | $9.1B | $8.4B | $11.9B | $17.0B |
| Capital spending | -$699M | -$563M | -$523M | -$585M | -$728M | -$579M | -$650M | -$825M | -$924M | -$590M | -$748M |
| Free cash flow | $13.8B | $9.5B | $10.3B | $7.4B | $8.3B | $10.8B | $7.5B | $8.3B | $7.5B | $11.3B | $16.3B |
| Dividends paid | $4.1B | $4.0B | $3.9B | $3.8B | $3.7B | $3.6B | $3.4B | $3.2B | $3.0B | $2.7B | $2.5B |
| Buybacks | $1.4B | $1.9B | $1.1B | $1.0B | $1.4B | $546M | $1.6B | $1.7B | $2.9B | $954M | $11.0B |
| Stock-based pay | $913M | $894M | $835M | $766M | $637M | $635M | $643M | $636M | $845M | $638M | $380M |
Balance sheet
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash | — | $7.6B | $10.0B | $7.3B | $6.4B | $6.5B | $7.4B | $24.4B | $30.1B | $25.5B | $11.9B |
| Debt | — | $25.5B | $27.3B | $25.7B | $25.8B | $27.3B | $32.1B | $25.3B | $27.8B | $33.5B | $26.3B |
| Equity | — | $22.7B | $19.3B | $22.8B | $21.2B | $21.1B | $18.2B | $22.5B | $21.4B | $20.4B | $18.9B |
| Total assets | — | $59.0B | $59.0B | $62.1B | $63.2B | $68.0B | $68.4B | $61.6B | $63.7B | $70.3B | $57.0B |
| Shares (diluted) | 1.25B | 1.25B | 1.25B | 1.26B | 1.26B | 1.26B | 1.26B | 1.28B | 1.31B | 1.32B | 1.36B |
Margins and returns
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 79.9% | 78.8% | 78.3% | 76.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% | 83.3% | 86.0% |
| Operating margin | -7.6% | 34.0% | 5.8% | 28.1% | 26.9% | 36.3% | 16.5% | 19.1% | 37.1% | 54.1% | 58.0% |
| Net margin | -12.5% | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.6% | 17.7% | 44.4% |
| FCF margin | 44.5% | 32.1% | 35.8% | 27.4% | 30.6% | 39.6% | 30.4% | 37.1% | 33.8% | 43.3% | 53.6% |
| ROIC | — | 18.1% | 2.5% | 12.8% | 12.2% | 15.4% | 6.4% | 7.1% | 11.7% | 20.7% | 30.8% |
| ROE | — | 37.5% | 2.5% | 24.8% | 21.6% | 29.5% | 0.7% | 23.9% | 25.5% | 22.6% | 71.5% |
Frequently asked questions
What is Gilead Sciences’s annual revenue?
$29.4B in fiscal 2025 and $31.0B over the twelve months to September 30, 2026.
How much profit does Gilead Sciences make?
Net income was $8.5B in fiscal 2025 (net margin 28.9%).
Is Gilead Sciences’s revenue growing?
Yes: revenue rose 2.4% in fiscal 2025 compared with the year before.
From the company’s 10-K and 10-Q filings with the SEC; per-share figures adjusted for stock splits. Rebuilt daily. Not investment advice.